The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.
Mar 1, 2013
By:
Adeline Siew, PhD
The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.
|
|
Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.
Mar 1, 2013
By:
Adeline Siew, PhD
Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.
|
Feb 27, 2013
By:
Adeline Siew, PhD
Belgium drug developer Ablynx and UK-based Spirogen have entered into a research collaboration to discover and develop novel anticancer drug conjugates combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBDs), and the company's associated linker technology, with nanobodies generated using Ablynx's proprietary technology platform.
|
Feb 26, 2013
By:
Adeline Siew, PhD
The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's six-in-one pediatric vaccine for marketing authorization.
|
Feb 25, 2013
By:
Adeline Siew, PhD
Merck's investigational integrin inhibitor cilengitide did not meet its primary endpoint in the CENTRIC Phase III trial evaluating if the agent could prolong overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy).
|
|
Feb 18, 2013
By:
Adeline Siew, PhD
Merck has agreed in principle to pay $688 million to settle two federal securities class-action lawsuits involving the company's anticholesterol drugs Vytorin and Zocor, thereby avoiding trial.
|
Feb 6, 2013
By:
Adeline Siew, PhD
Biotest Pharmaceuticals Corporation announced that Bivigam [immune globulin intravenous (human), 10% liquid] is now available in the pharmaceutical distribution channel for use by physicians, pharmacists and hospitals throughout the US. Bivigam is a sugar-free, glycine stabilized intravenous immune globulin that has been approved by the FDA in December 2012 for the treatment of patients with primary humoral immunodeficiency (PI).
|
Feb 5, 2013
By:
Adeline Siew, PhD
Shire announced that it has reached an agreement in principle with the US government to resolve the previously disclosed civil investigation into its sales and marketing practices in the US relating to the company's attention deficit hyperactivity disorder (ADHD) drugs, Adderall XR and Vyvanse as well as the ADHD patch Daytrana.
|
Feb 2, 2013
By:
Adeline Siew, PhD
Protecting patients from counterfeit medicines is a pressing issue facing governments and the pharmaceutical industry.
|
|
